Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Rand Sutherland

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Allergy and Asthma Proceedings|February 20, 2010
Comparative effect of body mass index on response to asthma controller therapyE Rand Sutherland, Carlos A Camargo, William W Busse, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|January 27, 2010
Body mass index and response to asthma therapy: fluticasone propionate/salmeterol versus montelukastCarlos A Camargo, Louis-Philippe Boulet, E Rand Sutherland, et al.
Pulmonary Pharmacology & Therapeutics|April 12, 2015
Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatmentIan P Hall, Andrew V Fowler, Abhya Gupta, et al.
The Journal of Allergy and Clinical Immunology|November 17, 2012
Obesity impairs apoptotic cell clearance in asthmaRuby Fernandez-Boyanapalli, Elena Goleva, Christena Kolakowski, et al.
American Journal of Respiratory and Critical Care Medicine|February 20, 2015
CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary DiseaseStephen I Rennard, David C Dale, James F Donohue, et al.
Plos One|May 19, 2012
Cluster analysis of obesity and asthma phenotypesE Rand Sutherland, Elena Goleva, Tonya S King, et al.
Journal of the American Academy of Dermatology|June 9, 2016
Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)Eric L Simpson, Abhijit Gadkari, Margitta Worm, et al.
American Journal of Respiratory and Critical Care Medicine|September 13, 2013
The effects of airway microbiome on corticosteroid responsiveness in asthmaElena Goleva, Leisa P Jackson, J Kirk Harris, et al.
American Journal of Respiratory and Critical Care Medicine|December 17, 2009
Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary diseasePrescott G Woodruff, Michael Wolff, Jens M Hohlfeld, et al.
Lancet (London, England)|May 1, 2016
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trialSally Wenzel, Mario Castro, Jonathan Corren, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Allergy and Asthma Proceedings|February 20, 2010
Comparative effect of body mass index on response to asthma controller therapyE Rand Sutherland, Carlos A Camargo, William W Busse, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|January 27, 2010
Body mass index and response to asthma therapy: fluticasone propionate/salmeterol versus montelukastCarlos A Camargo, Louis-Philippe Boulet, E Rand Sutherland, et al.
Pulmonary Pharmacology & Therapeutics|April 12, 2015
Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatmentIan P Hall, Andrew V Fowler, Abhya Gupta, et al.
The Journal of Allergy and Clinical Immunology|November 17, 2012
Obesity impairs apoptotic cell clearance in asthmaRuby Fernandez-Boyanapalli, Elena Goleva, Christena Kolakowski, et al.
American Journal of Respiratory and Critical Care Medicine|February 20, 2015
CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary DiseaseStephen I Rennard, David C Dale, James F Donohue, et al.
Plos One|May 19, 2012
Cluster analysis of obesity and asthma phenotypesE Rand Sutherland, Elena Goleva, Tonya S King, et al.
Journal of the American Academy of Dermatology|June 9, 2016
Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)Eric L Simpson, Abhijit Gadkari, Margitta Worm, et al.
American Journal of Respiratory and Critical Care Medicine|September 13, 2013
The effects of airway microbiome on corticosteroid responsiveness in asthmaElena Goleva, Leisa P Jackson, J Kirk Harris, et al.
American Journal of Respiratory and Critical Care Medicine|December 17, 2009
Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary diseasePrescott G Woodruff, Michael Wolff, Jens M Hohlfeld, et al.
Lancet (London, England)|May 1, 2016
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trialSally Wenzel, Mario Castro, Jonathan Corren, et al.
Pageof 8